title: [Sexual dysfunction in migraine patients who receive preventive treatment: identification by means of two screening tests].
abstract: BACKGROUND
  Sexual dysfunctions are one of the most important problems affecting sexual health and are associated with low levels of quality of life.
  
  
  OBJECTIVE
  To assess the sexual functioning in migraine patients and the sexual dysfunction that can be attributed to its preventive treatment.
  
  
  METHODS
  The patients attended in the headache units of two general hospitals who visited for the first time after being prescribed preventive treatment. They answered the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) and the Psychotropic-Related Sexual Dysfunction Questionnaire (SALSEX).
  
  
  RESULTS
  The sample used in the study consisted of 79 patients (17 males, 62 females) aged 37.6 ± 9.1 years (range: 19-57 years), 31 (39.2%) of them with chronic migraine. As preventive treatment, 23 (29.1%) received beta blockers; 42 (53.2%) neuromodulators; 8 (10.1%), calcium antagonists; and 6 (7.6%), antidepressants. The MGH-SFQ detected diminished overall sexual satisfaction that was at least moderate in 24 patients (30.4%). SALSEX showed changes in sexual functioning that was attributable to the preventive treatment in 36 cases (45.5%), which only exceptionally appeared spontaneously. In patients with at least moderate dysfunction on the MGH-SFQ, the mean ages at the time of testing, the number of days with pain per month and the excessive use of medication for their symptoms were all higher (53.3% versus 46.7%; p = 0.03).
  
  
  CONCLUSIONS
  Simple sexual dysfunction screening tests often detect sexual dysfunctions in patients with migraine on preventive treatment and changes in their sex life that can be attributed to these drugs.
authors.forename: Elena
authors.initials: E
authors.lastname: Domínguez
authors.forename: Lara
authors.initials: L
authors.lastname: Ruiz
authors.forename: Marta S
authors.initials: MS
authors.lastname: Hernández
authors.forename: Irene
authors.initials: I
authors.lastname: Muñoz
authors.forename: Marina
authors.initials: M
authors.lastname: Ruiz-Piñero
authors.forename: Fernando
authors.initials: F
authors.lastname: Uribe
authors.affiliation: Hospital Clinico Universitario de Valladolid, 47005 Valladolid, Espana.
authors.forename: Ángel L
authors.initials: ÁL
authors.lastname: Guerrero-Peral
authors.forename: M Elena
authors.initials: ME
authors.lastname: Toribio-Díaz
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001007:Anxiety / Q000453:epidemiology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D003863:Depression / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000453:epidemiology / Q000517:prevention & control*; D018377:Neurotransmitter Agents / Q000009:adverse effects / Q000627:therapeutic use; D009948:Orgasm / Q000187:drug effects; D010410:Penile Erection / Q000187:drug effects; D010549:Personal Satisfaction; D011446:Prospective Studies; D012720:Severity of Illness Index; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D002121:Calcium Channel Blockers; D018377:Neurotransmitter Agents